These results suggest that exposure to BFRs might result in a shift in the distribution of mammary cancer subtypes, showing, in this case, an increased proportion of TNBC tumors, and a decrease mainly in the HER2-enriched tumors. This evidence concerns the gene ERBB2 and breast cancer.